Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sets New 12-Month High - Here's What Happened

Key Points

• Shares of Swedish Orphan Biovitrum hit a new 52-week high of $47.4750 on Tuesday, after closing at $47.35, with 200 shares trading hands.
• Brokerage views are mixed but lean positive: BNP Paribas Exane upgraded to "outperform" and Barclays reaffirmed "overweight" while Danske cut to "hold," leaving an average rating of Moderate Buy (three Buys, one Hold).
• Sobi beat quarterly expectations with EPS of $0.45 vs. $0.38 expected and revenue of $755.8M vs. $749.8M, and the company carries a market cap of $16.9B and a high P/E of 158.25.

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) hit a new 52-week high during trading on Tuesday . The stock traded as high as $47.4750 and last traded at $47.4750, with a volume of 200 shares trading hands. The stock had previously closed at $47.35.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BIOVF. Barclays reaffirmed an "overweight" rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, February 24th. BNP Paribas Exane raised Swedish Orphan Biovitrum to an "outperform" rating in a research note on Tuesday, February 10th. Finally, Danske lowered Swedish Orphan Biovitrum to a "hold" rating in a research note on Thursday, February 19th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy".

Swedish Orphan Biovitrum Price Performance

The stock's fifty day moving average price is $40.22 and its two-hundred day moving average price is $37.13. The firm has a market capitalization of $16.90 billion, a price-to-earnings ratio of 158.25 and a beta of 0.34. The company has a current ratio of 0.90, a quick ratio of 0.59 and a debt-to-equity ratio of 0.14.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.45 earnings per share for the quarter, beating analysts' consensus estimates of $0.38 by $0.07. Swedish Orphan Biovitrum had a net margin of 3.37% and a return on equity of 17.23%. The business had revenue of $755.76 million for the quarter, compared to analyst estimates of $749.76 million.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi's strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company's marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.